KEIO RESEARCHERS INFORMATION SYSTEM

Career 【 Display / hide 】

Career 【 Display / hide 】

• 2003.04

  -

  2007.03

  鹿児島大学医学部・歯学部附属病院, 薬剤部, 医療職員

• 2007.04

  -

  2014.03

  鹿児島大学医学部・歯学部附属病院, 薬剤部, 主任

• 2014.04

  -

  2017.03

  慶應義塾大学薬学部, 実務薬学講座, 准教授

• 2017.04

  -

  Present

  慶應義塾大学薬学部, 薬効解析学講座, 教授

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 1994.04

  -

  1998.03

  Kumamoto University, 薬学部, 薬学科

  University, Graduated

• 1998.04

  -

  2000.03

  Kumamoto University, 薬学研究科

  Graduate School, Completed, Master's course

• 2000.04

  -

  2003.03

  Kumamoto University, 薬学研究科

  Graduate School, Completed, Doctoral course

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• 博士（薬学）, Kumamoto University, Coursework, 2003.03

  α1-酸性糖蛋白質の生理作用と動態特性に関する研究

Licenses and Qualifications 【 Display / hide 】

Licenses and Qualifications 【 Display / hide 】

• 薬剤師免許証, 1998.07

• 日本薬剤師研修センター認定薬剤師, 2006.03

• 日本医療薬学会認定薬剤師, 2009.01

• インフェクションコントロールドクター, 2009.01

• 感染制御専門薬剤師, 2009.03

display all >>

Research Areas 【 Display / hide 】

Research Areas 【 Display / hide 】

• Life Science / Clinical pharmacy

Research Keywords 【 Display / hide 】

Research Keywords 【 Display / hide 】

• Drug Delivery System

• 抗菌化学療法

• 高齢者医療

Research Themes 【 Display / hide 】

Research Themes 【 Display / hide 】

• 医薬品の薬効評価と副作用解析に基づいた薬物療法の最適化に関する研究, 

  2014.04

  -

  Present

Books 【 Display / hide 】

Books 【 Display / hide 】

• ケースで学ぶ老年薬学

  松元一明, 日経BP, 2024.01

  Scope: 感染症.

• 今日の治療指針2024

  松元一明, 医学書院, 2024.01

  Scope: 市中肺炎/急性中耳炎 服薬指導・薬剤情報

• 今日の治療薬2024

  松元一明, 南江堂, 2024.01

• マナビジュアルノート 感染症・病原体とくすり

  松元一明, 南山堂, 2023.12

• 薬がみえる vol 3 第2版

  松元一明, メディックメディア, 2023.09

  Scope: 抗菌薬/細胞壁合成阻害薬.

display all >>

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• Optimal Teicoplanin Trough Concentration With Therapeutic Drug Monitoring in Children: A Systematic Review and Meta-analysis.

  Hanai Y, Oda K, Ueda T, Matsumoto K, Murakami L, Uekusa S, Ohashi H, Nishimura K, Takesue Y, Matsuo K

  Therapeutic drug monitoring  2024.07

  Joint Work,  ISSN  0163-4356

  • Access to Document (DOI)

• Anti-edematous effects of epinastine, cetirizine and its enantiomers in λ-carrageenan-induced edema in rat hind paw

  Taguchi K., Chuang V.T.G., Ozawa M., Sakamoto Y., Hara R., Iketani O., Enoki Y., Kizu J., Hori S., Matsumoto K.

  Pharmazie （Pharmazie)  79 （ 6 ） 98 - 100 2024.06

  Joint Work,  ISSN  00317144

  　View Summary

  Urticaria is induced by the histamine released from mast cells which develops wheals (edema) as a visual feature. In clinical practice, second-generation histamine H1-receptor blockers are routinely used as the first-line symptomatic treatment for urticaria. Nevertheless, not much research has directly examined the second-generation histamine H1-receptor blockers’ ability to reduce edema. In this study, we directly evaluated the anti-edematous activities of three second-generation histamine H1-receptor blockers available in the market (epinastine hydrochloride, cetirizine hydrochloride, and levocetirizine hydrochloride) using a λ-carrageenan-induced footpad edema model. One hour before the induction of edema with 1% λ-carrageenan injection, all second-generation histamine H1-receptor blockers (5, 10, 50 and 100 mg/kg) were subcutaneously administered to rats. At 0.5 and 3 hours after λ-carrageenan administration, the edema volume was evaluated using a Plethysmometer. Epinastine hydrochloride significantly suppressed the edema growth in a dose-dependent manner. Cetirizine hydrochloride showed a slight anti-edematous effect, while levocetirizine significantly inhibited the development of edema in a dose-dependent manner. On the other hand, dextrocetirizine did not prevent edema from growing. In summary, second-generation histamine H1-receptor blockers, at least those examined in this study, may be able to reduce the clinical symptoms of urticaria associated with edema. Levocetirizine hydrochloride is also anticipated to have stronger anti-edematous effects than cetirizine hydrochloride because levocetirizine is responsible for cetirizine’s anti-edematous activity.

  • Access to Document (DOI)

• Relationship between nephrotoxicity and area under the concentration-time curve of vancomycin in critically ill patients: a multicenter retrospective study.

  Ishigo T, Matsumoto K, Yoshida H, Tanaka H, Ibe Y, Fujii S, Fukudo M, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Hamada Y, Samura M, Nagumoi F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Suzuki A

  Microbiology spectrum （Microbiology spectrum)  12 （ 7 ） e0373923 2024.05

  Joint Work

  　View Summary

  We aimed to assess the frequency of acute kidney injury (AKI) in different areas under the concentration-time curve (AUC) values of vancomycin (VAN) using a two-point blood collection method, allowing for accurate AUC assessment in critically ill patients. This multicenter retrospective observational study was conducted in eight hospitals. We retrospectively analyzed the data of patients who had received VAN in an intensive care unit (ICU) between January 2020 and December 2022. The primary outcome was the incidence of AKI. Patients were classified into three groups according to the AUC24-48h at the initial therapeutic drug monitoring (TDM) as follows: <500, 500-600, and ≥600 µg·h/mL. The AUC24-48h values were calculated using the Bayesian estimation software Practical AUC-guided TDM. Among 146 patients [median age (interquartile range), 67 (56-78) years; 39% women], the AUC24-48h <500 µg·h/mL had an AKI rate of 6.5% (7/107), the AUC24-48h 500-600 µg·h/mL had an AKI rate of 28.0% (7/25), and the AUC24-48h ≥600 µg·h/mL had an AKI rate of 42.9% (6/14). In multivariate Cox proportional hazard analysis, the AUC24-48h 500-600 µg·h/mL [hazard ratio 5.4, 95% confidence interval (CI) 1.64-17.63] and the AUC24-48h ≥600 μg·h/mL (hazard ratio 7.0, 95% CI 2.31-21.18) significantly correlated with a higher incidence of AKI compared with the AUC24-48h <500 μg·h/mL. In conclusion, we identified an association between AUC on day 2 and the risk of AKI in ICU patients, suggesting that not only AUCs above 600 µg·h/mL but also those between 500 and 600 µg·h/mL pose a risk for AKI. IMPORTANCE: Vancomycin (VAN) is a glycopeptide antibiotic and one of the most commonly used antibiotics for severe infections caused by methicillin-resistant Staphylococcus aureus. However, higher VAN concentrations have been associated with an increased risk of acute kidney injury (AKI). Herein, we aimed to assess the frequency of AKI in different areas under the concentration-time curve (AUC) values of VAN using a two-point blood collection method, allowing for accurate AUC assessment in critically ill patients. We identified an association between AUC on day 2 and the risk of AKI in intensive care unit patients, suggesting that not only AUCs above 600 µg·h/mL but also those between 500 and 600 µg·h/mL pose a risk for AKI. Therefore, individualized dosing is feasible, with pharmacists being able to optimize VAN doses to attain appropriate targets.

  • Access to Document (DOI)

• Direct comparison of anti-inflammatory effects of 14-, 15-, and 16-membered macrolide antibiotics in experimental inflammation model induced by carrageenan in rats.

  Taguchi K, Chuang VTG, Ogino H, Hara R, Iketani O, Enoki Y, Kizu J, Hori S, Matsumoto K

  Die Pharmazie （Pharmazie)  79 （ 3 ） 64 - 66 2024.05

  Joint Work,  ISSN  0031-7144

  　View Summary

  Some macrolide antibiotics, which share a basic lactone ring structure, also exhibit anti-inflammatory actions in addition to their antibacterial activities. However, no study has directly compared anti-inflammatory effects on acute inflammation among macrolide antibiotics with the distinct size of the lactone ring. In this study, we evaluated and compared the anti-inflammatory activities of four 14-membered macrolides (erythromycin, clarithromycin, roxithromycin, oleandomycin), one 15-membered macrolide (azithromycin), and three 16-membered macrolides (midecamycin, josamycin, leucomycin) using a rat carrageenan-induced footpad edema model. All macrolide antibiotics were intraperitoneally administered to rats one hour before the induction of inflammatory edema with 1% λ-carrageenan. The anti-inflammatory effects on acute inflammation were evaluated by changing the edema volume. All 14-membered and 15-membered macrolide antibiotics significantly suppressed the development of edema. Conversely, none of the 16-membered macrolide antibiotics inhibited the growth of edema. In conclusion, compared to 16-membered macrolide antibiotics, 14-membered and 15-membered macrolide antibiotics have stronger anti-inflammatory effects. Further research should be done to determine why different lactone ring sizes should have distinct anti-inflammatory effects.

  • Access to Document (DOI)

• Dual delivery of carbon monoxide and doxorubicin using haemoglobin-albumin cluster: proof of concept for well-tolerated cancer therapy.

  Ito C, Taguchi K, Yamada T, Hanaya K, Enoki Y, Sugai T, Komatsu T, Matsumoto K

  Journal of materials chemistry. B （Journal of Materials Chemistry B)  12 （ 23 ） 5600 - 5608 2024.05

  Joint Work,  ISSN  2050-750X

  　View Summary

  A serious concern of doxorubicin (DOX) therapy is that it causes severe adverse effects, particularly cardiotoxicity. Carbon monoxide (CO) possesses powerful cytoprotective effects against drug-induced organ injury and is expected to ameliorate DOX-induced cardiotoxicity. In this study, a dual carrier of DOX and CO (CO-HemoAct-DOX) was fabricated based on a haemoglobin-albumin cluster (HemoAct), which is a protein cluster with a haemoglobin core structure wrapped by serum albumin. CO-HemoAct-DOX was synthesised by binding CO to a haemoglobin core and covalently conjugating (6-maleimidocaproyl)hydrazone derivative of DOX to an albumin shell. The average DOX/cluster ratio was about 2.6. In the in vitro cytotoxicity assay against cancer cells, the anti-tumour activity of CO-HemoAct-DOX was 10-fold lower than that of DOX in a 2D-cultured model, whereas CO-HemoAct-DOX suppressed the growth of tumour spheroids to the same extent as DOX in the 3D-cultured model. In colon-26 tumour-bearing mice, CO-HemoAct-DOX achieved DOX delivery to the tumour site and alleviated tumour growth more effectively than DOX. Furthermore, CO-HemoAct attenuated DOX-induced cardiomyocyte atrophy in H9c2 cells and elevated the levels of cardiac biomarkers in mice exposed to DOX. These results suggest that the dual delivery of CO and DOX using HemoAct is a promising strategy as an anti-tumour agent to realise well-tolerated cancer therapy with minimal cardiotoxicity.

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• In vitro PK/PD evaluation for rapid development of therapeutic drugs for IMP-type MBL-producing bacterial infections

  Matsumoto, Kazuaki

  学事振興資金研究成果実績報告書 （慶應義塾大学)  2022

• Development of novel in vivo PK/PD evaluation models against CDI and its application

  Matsumoto, Kazuaki

  福澤諭吉記念慶應義塾学事振興基金事業報告集 （福澤基金運営委員会)  2021

• Development of individually optimized dosing regimen for antimicrobial agents aiming at overcoming antimicrobial-resistant bacterial infections

  Matsumoto, Kazuaki

  科学研究費補助金研究成果報告書 2020

Reviews, Commentaries, etc. 【 Display / hide 】

Reviews, Commentaries, etc. 【 Display / hide 】

• 同種造血幹細胞移植後にポサコナゾール腸溶錠の血中濃度が低値を示した一例

  島村 千陽, 坂本 靖宜, 長谷川 拓也, 榎木 裕紀, 田口 和明, 松元 一明

  日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 116 - 116 2024.01

  ISSN  1340-7007

• バンコマイシン投与で2点採血を実施した患者における1点採血と2点採血の比較

  鈴木 絢子, 佐村 優, 石郷 友之, 伊部 裕太, 相神 智宏, 吉田 博昭, 田中 宏明, 海老原 文哉, 丸山 拓実, 南雲 史雄, 小松 敏彰, 冨澤 淳, 千葉 博暁, 詫間 章俊, 榎木 裕紀, 田口 和明, 浜田 幸宏, 西 圭史, 藤居 賢, 松元 一明, 山口 史博, 藤原 久登

  日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 109 - 109 2024.01

  ISSN  1340-7007

• デキストラン硫酸ナトリウム誘発性炎症性腸疾患マウスモデルを用いたfidaxomicinとvancomycinの抗炎症効果比較

  三原 貴之, 榎木 裕紀, 田口 和明, 松元 一明

  日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 95 - 95 2024.01

  ISSN  1340-7007

• Mycobacterium avium complexに対するβ-ラクタム系抗菌薬2剤併用の有効性評価

  吉川 万衣子, 西村 知泰, 三澤 可奈, 島村 莉奈, 榎木 裕紀, 田口 和明, 松元 一明, 長谷川 直樹

  日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 97 - 98 2024.01

  ISSN  1340-7007

• Mycobacterium abscessusのコロニー形態は抗菌薬濃度によって変化する

  島村 莉奈, 西村 知泰, 三澤 可奈, 吉川 万衣子, 榎木 裕紀, 田口 和明, 松元 一明, 長谷川 直樹

  日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 98 - 98 2024.01

  ISSN  1340-7007

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築.

  並木孝哉、横山雄太、枦秀樹、織田錬太郎、地引綾、河添仁、松元一明、鈴木小夜、中村智徳.

  第44回日本臨床薬理学会学術総会 (兵庫県) , 

  2023.12

  , 

  Oral presentation (general)

• 第2部：抗微生物薬の選択と投与「TDMガイドラインのupdate」

  松元一明.

  敗血症WEBセミナー2023 微生物との対峙 (東京都) , 

  2023.12

  , 

  Public lecture, seminar, tutorial, course, or other speech

• 抗菌薬投与によるMycobacterium abscessusのコロニー形態変化.

  島村莉奈、西村知泰、三澤可奈、吉川万衣子、柏村祥子、矢野大和、矢野郁也、榎木裕紀、田口和明、松元一明、長谷川直樹.

  第54回結核・非定型抗酸菌症治療研究会 (東京都) , 

  2023.12

  , 

  Oral presentation (general)

• Mycobacterium abscessus complexに対してナキュバクタムとβラクタム系薬2剤併用は有効である.

  三澤可奈、西村知泰、吉川万衣子、島村莉奈、柏村祥子、榎木裕紀、田口和明、松元一明、長谷川直樹.

  第54回結核・非定型抗酸菌症治療研究会 (東京都) , 

  2023.12

  , 

  Oral presentation (general)

• 薬剤感受性試験によるMycobacterium avium complexに対するβ-ラクタム系抗菌薬2剤併用の有効性評価.

  吉川万衣子、西村知泰、三澤可奈、島村莉奈、柏村祥子、榎木裕紀、田口和明、松元一明、長谷川直樹.

  第54回結核・非定型抗酸菌症治療研究会 (東京都) , 

  2023.12

  , 

  Oral presentation (general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• 新規肺MABC症治療薬の開発と革新的非臨床PK/PD評価法の構築

  2024.04

  -

  2028.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

• 薬剤耐性淋菌・緑膿菌に有効な新規抗菌剤の開発

  2023.08

  -

  2024.03

  国立研究開発法人日本医療研究開発機構（AMED）, 新興・再興感染症に対する革新的医薬品等開発推進研究事業, Joint research, Coinvestigator(s)

• ホローファイバー感染モデルを用いたカルバペネム耐性菌感染症の抗菌薬併用療法に関する橋渡し研究

  2022.04

  -

  2025.03

  国立研究開発法人国立国際医療研究センター, 国際医療研究開発事業, Joint research, Coinvestigator(s)

• マウス肺感染モデルを用いたOP0595の臨床有効性予測

  2022.01

  -

  2024.03

  Meiji Seikaファルマ株式会社, Commissioned ｒesearch, Principal investigator

• Investigation of the effectiveness of imeglimin as a potential therapeutic agent for sarcopenia

  2021.09

  -

  2023.08

  大日本住友製薬株式会社, Commissioned ｒesearch, Principal investigator

display all >>

Intellectual Property Rights, etc. 【 Display / hide 】

Intellectual Property Rights, etc. 【 Display / hide 】

• メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

  Date applied： 特願2020-144044  2020.08 

  Patent, Joint

Awards 【 Display / hide 】

Awards 【 Display / hide 】

• 第44回日本臨床薬理学会学術総会優秀発表賞

  並木孝哉、横山雄太、枦秀樹、織田錬太郎、地引綾、河添仁、松元一明、鈴木小夜、中村智徳., 2023.12, 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築.

• 第17回日本腎臓病薬物療法学会学術集会・総会2023優秀演題賞

  石郷友之、藤居賢、伊部裕太、吉田博昭、田中宏明、海老原文哉、丸山拓実、鈴木絢子、佐村優、南雲史雄、小松敏彰、冨澤淳、詫間章俊、千葉博暁、榎木裕紀、田口和明、浜田幸宏、西圭史、松元一明、福土将秀., 2023.10,  ICU症例におけるバンコマイシンの急性腎障害と早期AUCとの関連性.

• 日本薬学会第143年会 学生優秀発表賞 口頭発表の部

  長邑花, 榎木裕紀, 田口和明, 松元一明., 2023.04, 骨格筋萎縮による敗血症病態の増悪と免疫状態変動の関与.

• 第14回日本化学療法学会東日本支部 支部長賞（基礎）

  田代渉、榎木裕紀、田口和明、松元一明, 2023.01, Clostridioides difficileに対するfidaxomicinのin vitro抗菌活性評価及びin vivo感染マウスモデルを用いた糞中PK/PD評価

• 第29回日本血液代替物学会年次大会学生講演賞

  伊藤千尋、田口和明、山田大雅、榎木裕紀、小松晃之、松元一明, 2022.12, ドキソルビシン担持一酸化炭素結合型ヘモグロビン-アルブミンクラスターの創製と抗腫瘍効果の評価

display all >>

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• STUDY OF MAJOR FIELD (PHARMACODYNAMICS)

  2024

• SEMINAR (PHARMACODYNAMICS)

  2024

• RESEARCH FRONTIERS IN BIOMEDICAL SCIENCE

  2024

• RESEARCH FOR BACHELOR'S THESIS 1

  2024

• PROJECT FOR MULTIDISCIPLINARY AND INTERDISCIPLINARY KNOWLEDGE (SUSTAINABLE ENVIRONMENT)

  2024

display all >>

Social Activities 【 Display / hide 】

Social Activities 【 Display / hide 】

• 薬剤耐性菌感染症治療薬の臨床評価に関する報告書

  独立行政法人医薬品医療機器総合機構

  2019.08

  -

  2020.10

Memberships in Academic Societies 【 Display / hide 】

Memberships in Academic Societies 【 Display / hide 】

• 日本医真菌学会, 

  2019.02

  -

  Present

• 日本DDS学会, 

  2018.05

  -

  Present

• 日本臨床微生物学会, 

  2018.03

  -

  Present

• 日本老年薬学会　理事・評議員, 

  2016.04

  -

  Present

• 日本薬剤学会, 

  2015.12

  -

  Present

display all >>